Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment-Reference-Cited by-同舟云学术

Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment

Published:2013-12 Issue:2 Volume:231 Page:392-400
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Becatti Matteo,Fiorillo Claudia,Gori Anna Maria,Marcucci Rossella,Paniccia Rita,Giusti Betti,Violi Francesco,Pignatelli Pasquale,Gensini Gian Franco,Abbate Rosanna

Funder

Ministero della Salute

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference44 articles.

1. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI;Parodi;JAMA,2011

2. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents;Gori;J Am Coll Cardiol,2008

3. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up;Marcucci;Circulation,2009

4. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery;Ferreiro;Thromb Haemost,2013

5. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy;Marcucci;Atherosclerosis,2007

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SIRT1 and thrombosis;Frontiers in Molecular Biosciences;2024-01-18

2. Correlation Studies between MPVLR, Cystatin (Cysc), and Myocardial Vulnerability Phase;Advances in Clinical Medicine;2024

3. ROS-driven structural and functional fibrinogen modifications are reverted by interleukin-6 inhibition in Giant Cell Arteritis;Thrombosis Research;2023-10

4. Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease;Journal of Pharmaceutical Negative Results;2022-11-12

5. A new marker of short-term mortality and poor outcome in patients with acute ischemic stroke: Mean platelet volume-to-lymphocyte ratio;Medicine;2022-10-07